Robert Francomano is a tenured and distinguished Chief Commercial Officer with extensive experience in elevating oncology clinical-stage organizations to global commercial prominence. His expertise is underpinned by a compelling track record of exceeding financial goals through the deployment of sophisticated commercialization strategies. In recent roles, Robert achieved the number one ranked impact on stock price growth percentage for biotech organizations executing their first commercial product launch. Throughout Robert’s illustrious career, he has proven an innate ability to propel his organizations forward. As Chief Commercial Officer of both SELLAS Life Sciences and Stemline Therapeutics, he was the architect of building and integrating a commercial operations to support and/or drive revenue generation. His strategic leadership at Stemline Therapeutics culminated in surpassing Wall Street’s first full-year revenue projections by 175% following the successful U.S. launch and commercialization of their premier product. This achievement not only reflects his adeptness in strategic planning and execution but also his capacity to significantly influence market perceptions and investor confidence.